中国医药
中國醫藥
중국의약
CHINA MEDICINE
2013年
11期
1539-1541
,共3页
原发性混合型高脂血症%吉非贝齐%辛伐他汀
原髮性混閤型高脂血癥%吉非貝齊%辛伐他汀
원발성혼합형고지혈증%길비패제%신벌타정
Primary mixed hyperlipidemia%Gemfibrozil%Simvastatin
目的 观察吉非贝齐联合低剂量辛伐他汀治疗老年原发性混合型高脂血症的临床疗效.方法 选择2010年7月至2012年12月广东省深圳市福田区第二人民医院治疗的原发性混合型高脂血症老年患者(年龄≥65岁)150例,随机数字表法分为对照组(75例)与观察组(75例).对照组服用辛伐他汀20 mg/d,观察组联合服用吉非贝齐300～600 mg/d、辛伐他汀10 mg/d,2组疗程均为6周.观察2组治疗后的总有效率、TC、TG、LDL-C、HDL-C以及血压变化情况.结果 治疗6周后,观察组总有效率为98.7％(74/75),对照组为92.0％ (69/75),2组比较差异有统计学意义(P＜0.05).2组治疗后TC、TG、LDL-C、HDL-C水平[观察组:(4.6±0.5)、(1.2±0.3)、(2.4±0.6)、(1.5±0.3) mmol/L;对照组:(4.9±0.4)、(1.6±0.3)、(3.0±0.5)、(1.0±0.3)mmol/L]与治疗前[观察组:(7.1±0.6)、(2.3±0.3)、(4.1±0.4)、(0.9±0.4)mmoL/L;对照组:(7.0±0.6)、(2.3±0.3)、(4.1±0.4)、(0.9±0.4) mmol/L]比较,差异均有统计学意义(均P＜0.05).观察组治疗后TC、TG、LDL-C、HDL-C与对照组比较,差异均有统计学意义(均P＜0.05).治疗后2组收缩压、舒张压[观察组:(132±7)、(83 ±6)mm Hg(1 mm Hg =0.133 kPa)；对照组:(140±6)、(87 ±6)mm Hg]均低于本组治疗前[观察组:(156±10)、(97 ±8)mm Hg;对照组:(157±8)、(96±6)mm Hg],差异有统计学意义(均P ＜0.05)；治疗后观察组收缩压、舒张压与对照组比较,差异有统计学意义(均P＜0.05).结论 吉非贝齐联合低剂量辛伐他汀可有效改善老年原发性混合型高脂血症,降低TC、TG、LDL-C水平,提高HDL-C水平,并有效改善患者血压.
目的 觀察吉非貝齊聯閤低劑量辛伐他汀治療老年原髮性混閤型高脂血癥的臨床療效.方法 選擇2010年7月至2012年12月廣東省深圳市福田區第二人民醫院治療的原髮性混閤型高脂血癥老年患者(年齡≥65歲)150例,隨機數字錶法分為對照組(75例)與觀察組(75例).對照組服用辛伐他汀20 mg/d,觀察組聯閤服用吉非貝齊300～600 mg/d、辛伐他汀10 mg/d,2組療程均為6週.觀察2組治療後的總有效率、TC、TG、LDL-C、HDL-C以及血壓變化情況.結果 治療6週後,觀察組總有效率為98.7％(74/75),對照組為92.0％ (69/75),2組比較差異有統計學意義(P＜0.05).2組治療後TC、TG、LDL-C、HDL-C水平[觀察組:(4.6±0.5)、(1.2±0.3)、(2.4±0.6)、(1.5±0.3) mmol/L;對照組:(4.9±0.4)、(1.6±0.3)、(3.0±0.5)、(1.0±0.3)mmol/L]與治療前[觀察組:(7.1±0.6)、(2.3±0.3)、(4.1±0.4)、(0.9±0.4)mmoL/L;對照組:(7.0±0.6)、(2.3±0.3)、(4.1±0.4)、(0.9±0.4) mmol/L]比較,差異均有統計學意義(均P＜0.05).觀察組治療後TC、TG、LDL-C、HDL-C與對照組比較,差異均有統計學意義(均P＜0.05).治療後2組收縮壓、舒張壓[觀察組:(132±7)、(83 ±6)mm Hg(1 mm Hg =0.133 kPa)；對照組:(140±6)、(87 ±6)mm Hg]均低于本組治療前[觀察組:(156±10)、(97 ±8)mm Hg;對照組:(157±8)、(96±6)mm Hg],差異有統計學意義(均P ＜0.05)；治療後觀察組收縮壓、舒張壓與對照組比較,差異有統計學意義(均P＜0.05).結論 吉非貝齊聯閤低劑量辛伐他汀可有效改善老年原髮性混閤型高脂血癥,降低TC、TG、LDL-C水平,提高HDL-C水平,併有效改善患者血壓.
목적 관찰길비패제연합저제량신벌타정치료노년원발성혼합형고지혈증적림상료효.방법 선택2010년7월지2012년12월광동성심수시복전구제이인민의원치료적원발성혼합형고지혈증노년환자(년령≥65세)150례,수궤수자표법분위대조조(75례)여관찰조(75례).대조조복용신벌타정20 mg/d,관찰조연합복용길비패제300～600 mg/d、신벌타정10 mg/d,2조료정균위6주.관찰2조치료후적총유효솔、TC、TG、LDL-C、HDL-C이급혈압변화정황.결과 치료6주후,관찰조총유효솔위98.7％(74/75),대조조위92.0％ (69/75),2조비교차이유통계학의의(P＜0.05).2조치료후TC、TG、LDL-C、HDL-C수평[관찰조:(4.6±0.5)、(1.2±0.3)、(2.4±0.6)、(1.5±0.3) mmol/L;대조조:(4.9±0.4)、(1.6±0.3)、(3.0±0.5)、(1.0±0.3)mmol/L]여치료전[관찰조:(7.1±0.6)、(2.3±0.3)、(4.1±0.4)、(0.9±0.4)mmoL/L;대조조:(7.0±0.6)、(2.3±0.3)、(4.1±0.4)、(0.9±0.4) mmol/L]비교,차이균유통계학의의(균P＜0.05).관찰조치료후TC、TG、LDL-C、HDL-C여대조조비교,차이균유통계학의의(균P＜0.05).치료후2조수축압、서장압[관찰조:(132±7)、(83 ±6)mm Hg(1 mm Hg =0.133 kPa)；대조조:(140±6)、(87 ±6)mm Hg]균저우본조치료전[관찰조:(156±10)、(97 ±8)mm Hg;대조조:(157±8)、(96±6)mm Hg],차이유통계학의의(균P ＜0.05)；치료후관찰조수축압、서장압여대조조비교,차이유통계학의의(균P＜0.05).결론 길비패제연합저제량신벌타정가유효개선노년원발성혼합형고지혈증,강저TC、TG、LDL-C수평,제고HDL-C수평,병유효개선환자혈압.
Objective To observe the clinical efficacy of gemfibrozil combined with low doses of Simvastatin in the treatment of elderly patients with primary mixed hyperlipidemia.Methods One hundred and fifty elderly patients with primary mixed hyperlipidemia (age ≥65 years) in the second people's hospital of Futian district in Shenzhen city from July 2010 to December 2012 were randomly divided into control group (75 cases) and the observation group (75 cases) by the random number table.The control group received simvastatin 20 mg/d.The observation group received gemfibrozil (300-600 mg/d) and simvastatin (10 mg/d).After six weeks,the total effective rate,total cholesterol (TC),triglyceride (TG),low-density lipoprotein cholesterol (LDL-C),high-density lipoproteincholesterol (HDL-C) and blood pressure of two groups were compared.Results After 6 weeks of treatment,the total effective rate of observation group was 98.7％ while the control group was 92.0％ ; the difference was statistically significant (P ＜ 0.05).There were significant differences on TC,TG,LDL-C,HDL-C levels between two groups [observation group:(4.6 ± 0.5),(1.2 ± 0.3),(2.4 ± 0.6),(1.5 ± 0.3) mmol/L; contiol group:(4.9 ± 0.4),(1.6 ± 0.3),(3.0 ± 0.5),(1.0 ± 0.3) mmol/L] after treatment compared with those before treatment [observation group:(7.1 ± 0.6),(2.3 ± 0.3),(4.1 ± 0.4),(0.9 ± 0.4) mmol/L; control group:(7.0 ± 0.6),(2.3 ± 0.3),(4.1 ± 0.4),(0.9 ± 0.4) mmol/L] (P ＜ 0.05).There were significant differences on TC,TG,LDL-C,HDL-C levels of observation group after treatment compared with control group (P ＜ 0.05).After treatment,systolic blood pressure and diastolic blood pressure of two groups [observation group:(132 ± 7),(83 ± 6)mm Hg; control group:(140 ± 6),(87 ± 6) mm Hg] were lower than before treatment [observation group:(156 ± 10),(97 ± 8) mm Hg; control group:(157 ± 8),(96 ± 6) mm Hg] (P ＜ 0.05).There were significant differences on systolic blood pressure and diastolic blood pressure of observation group compared with control group (P ＜ 0.05).Conclusions Gemfibrozil combine with low dose simvastatin is effective for the elderly patients with primary mixed hyperlipidemia.It can reduce the level of TC,TG,LDL-C,increase the level of HDL-C and effectively improve the patient's blood pressure.
